Bristol Myers Squibb (CELG-RI) Income from Discontinued Operations (2009)
Bristol Myers Squibb (CELG-RI) posted quarterly Income from Discontinued Operations of 61000000.0 for Q4 2009, down 167.03% quarter-over-quarter from 91000000.0 in Q3 2009.
Bristol Myers Squibb (CELG-RI) Income from Discontinued Operations (2009) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Income from Discontinued Operations for 1 consecutive years, with 61000000.0 the latest figure, recorded in Q4 2009.
- In Q4 2009, Income from Discontinued Operations changed N/A year-over-year to 61000000.0; the TTM figure through Dec 2009 stood at 160000000.0 (changed N/A YoY), while the FY2009 annual figure was 285000000.0, changed N/A from the prior year.
- Income from Discontinued Operations eased to 61000000.0 in Q4 2009 per CELG-RI's latest filing, from 91000000.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 129000000.0 in Q2 2009 and bottomed at 61000000.0 in Q4 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 8.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2009 | -61.00 Mn |
| Sep 30, 2009 | 91.00 Mn |
| Jun 30, 2009 | 129.00 Mn |
| Mar 31, 2009 | 1.00 Mn |